Brief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
08/10/2026 14:25
BRIEF-Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body Oct 8 (Reuters) - Biofrontera Inc BFRI.O:
BIOFRONTERA SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA TO EXPAND AMELUZ® RED LIGHT PDT TO ACTINIC KERATOSES ON THE FULL BODY
Source text: ID:nGNX1VLWRL
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales